Myomo (MYO) Insider JR. Buys 78,704 Shares

Thomas Aloysius Jr. recently bought 78,704 shares of Myomo, Inc., a medical device company, on June 25, 2026. This transaction did not involve a pre-planned trading arrangement. On the same day, shares of Myomo traded around $1.14.

Insider Buying and Selling at Myomo, Inc.

Several insiders at Myomo, Inc. were active in the market recently. Thomas Aloysius Jr., along with Kirk Thomas and Joseph Manko Jr., each acquired 78,704 shares on June 25, 2026. Meanwhile, on June 12, 2026, Chief Financial Officer David Henry, Chief Medical Officer Harry Kovelman, and Chief Commercial Officer Micah Mitchell sold 10,969, 10,442, and 9,061 shares, respectively.

Other Institutional Activity in Myomo, Inc.

In recent institutional activity, Rosalind Advisors, Inc. increased its holdings by 7,500 shares, bringing its total to 3,847,272 shares valued at approximately $2.6 million. BlackRock, Inc. slightly reduced its position by 24,389 shares, now holding 1,688,390 shares worth about $1.1 million. Vanguard Capital Management LLC initiated a new position with 1,144,324 shares valued at $773,563. Geode Capital Management, LLC grew its stake by 121,830 shares to a total of 858,799 shares, worth around $580,274.

Myomo, Inc. Stock Down 28.2%

As of Saturday, Myomo, Inc. (NYSE American: MYO) traded near $1.14. The company boasts a market capitalization of roughly $41.7 million and a beta of 1.46, indicating higher volatility compared to the market. The stock's 52-week range spans from $0.60 to $2.38. Myomo's 50-day moving average is $1.02, while its 200-day moving average stands at $0.91. The company's current ratio is 2.73, with a quick ratio of 2.19 and a debt-to-equity ratio of 210.65.

Analysts Set New Price Targets

On June 8, 2026, Ascendiant Capital maintained its 'buy' rating on Myomo, Inc. with a price target of $10. The consensus among analysts is a 'buy' recommendation, with an average target price of $4.42 based on five opinions.

About Myomo, Inc.

Myomo, Inc., headquartered in Burlington, Massachusetts, is a healthcare company specializing in wearable medical robotics. It designs and produces myoelectric orthotics aimed at helping individuals with neuromuscular disorders. The company’s flagship product, the MyoPro, assists patients with weak or paralyzed arms, enhancing their ability to perform daily tasks. Myomo operates in the United States and internationally, employing about 194 people under the leadership of CEO Paul R. Gudonis.

Bottom Line

Thomas Aloysius Jr.'s recent purchase of Myomo shares is part of broader insider activity at the company. Investors often track such transactions for potential insights into company prospects. It's important to note that these filings are retrospective and may not reflect current positions.